A Bengaluru-based biotechnology company has developed an artificial intelligence-powered blood test that could help identify signals linked to multiple types of cancer through a single blood sample. The test, called CancerSpot, uses DNA sequencing and artificial intelligence to analyse changes in genetic material circulating in the bloodstream.
The development has attracted attention because detecting several cancers through one test could potentially improve early screening and support timely medical evaluation.
How Does CancerSpot Work?
CancerSpot analyses cell-free DNA, which consists of small DNA fragments circulating in the blood. It examines DNA methylation patterns, which can provide clues about changes associated with different cancers.
The technology was developed by Strand Life Sciences and is designed to identify signals associated with 14 cancer types without requiring a separate tissue biopsy for the initial blood-based analysis.
Study Included 1,480 Participants
The research involved 1,480 participants across 43 hospitals in India over four years. In an independent validation group, the test detected 72% of cancer cases, with a false-positive rate of 1.4%.
What Could This Mean for Cancer Screening?
Researchers believe multi-cancer detection technology could eventually become an additional tool for identifying people who may need further medical investigations.
However, CancerSpot is not a replacement for established cancer screening methods or diagnostic confirmation. Its reported results require further clinical evaluation before its wider use can be established.
The development represents an encouraging step in India’s growing field of AI-assisted medical research, although its practical role in routine healthcare will depend on additional evidence and validation.
